Uncertainties

In this guide

In this guide

- 1. Background and Introduction Garcinia cambogia oral consumption
- 2. Data from authoritative bodies Garcinia cambogia oral consumption
- 3. Chemical composition Garcinia cambogia oral consumption
- 4. ANSES Garcinia cambogia oral consumption
- 5. AESAN Garcinia cambogia oral consumption
- 6. Australian TGA Garcinia cambogia oral consumption
- 7. <u>BfR (German Federal Institute for Risk Assessment) Garcinia cambogia oral</u> consumption
- 8. EFSA Garcinia cambogia oral consumption
- 9. Health Canada Garcinia cambogia oral consumption
- 10. NCCIH Garcinia cambogia oral consumption
- 11. Data from literature search Garcinia cambogia oral consumption
- 12. Human data Garcinia cambogia oral consumption
- 13. Hepatotoxic case reports Garcinia cambogia oral consumption
- 14. Animal studies Garcinia cambogia oral consumption
- 15. Exposure Garcinia cambogia oral consumption
- 16. Uncertainties Garcinia cambogia oral consumption
- 17. Risk Characterisation Garcinia cambogia oral consumption
- 18. Questions to the Committee Garcinia cambogia oral consumption
- 19. Abbreviations Garcinia cambogia oral consumption
- 20. References Garcinia cambogia oral consumption

This is a discussion paper. It does not reflect the views of the Committee. It should not be cited.

- 195. The following uncertainties have been noted:
 - Dietary supplement labels often do not list the full scientific name/specie of G. cambogia nor the part of the plant that the extract(s) is/are derived from. This represents an uncertainty as it does not allow accurate determination of

the components of the food product (including food supplements).

- *G. cambogia* products have inconsistent labelling. Some are simply marketed as *G. cambogia* or *G. cambogia* extract without describing whether it is HCA nor the standardised HCA content. This poses an issue for both exposure and risk assessment as the HCA content is unknown.
- The percentage of standardised HCA in G. cambogia extract or the salt form
 of HCA in food supplement products is not always disclosed and there is
 inconsistency in labelling of said products. Depending on the amount of
 concentrate and the form of HCA salt, the toxicological profile could
 potentially be different.
- *G. cambogia* (and/or its extract; HCA) is more commonly present in MIDS that have other active compounds that may or may not be fully disclosed, which does not allow for a comprehensive risk assessment.
- If *G. cambogia* (and/or its extract) is present in MIDS there is a potential synergistic effect of the mixture, the potential risk(s) of which is unknown.
- Consumers may use more than one HIDS and/or in combination with prescription drugs. Incorrect dosing is also possible should the consumer not follow the manufacturers' instructions.
- Considerations for the presence of contaminants such as heavy metals, extraction solvents (from the manufacturing process), pesticides or any other chemicals that could pose a risk to health have not been considered in this assessment.
- Case reports in the literature are limited to certain brands and formulations of *G. cambogia* and may not always provide the holistic state of the consumer: granularity on duration of exposure and dose, health status of the consumer (*e.g.*, do they have suspected liver injury or immunocompromised or any other, fasting or non-fasting, physically active or not active), concomitant with other drugs or MIDS. Thus, identification of sensitive population and establishment of a mode of action for the toxicity observed in these cases is always not possible.
- Possible drug-drug interactions have been reported in some case-studies (
 e.g., anti-depression (serotonergic drugs), drugs affecting the liver).
 However, there is little scientific information to be able to fully assess this potential risk. Furthermore, it is unknown if other types of medication can cause adverse drug interaction.
- The long-term safety of *G. cambogia* (and/or its extract; HCA) has not been established.